After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies with smoked turkey and ham drew the crowd, but several people lingered for ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus.  In this study, ...

Gilead Sciences adds $11B to its U.S. investment plan, boosting manufacturing, R&D, and job creation. Read more here.

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study. The companies said the trial met its ...

The South San Francisco company has enticed Gilead with its vision of using AI and machine learning to transform drug discovery, getting $15 million in upfront backing in a deal that could be ...